Back to News
Market Impact: 0.25
Lilly's Zepbound Use Linked To Lower Healthcare Costs In Older Adults
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsConsumer Demand & RetailAnalyst Insights
Eli Lilly reported real-world study results indicating sustained Zepbound use in adults over 55 with overweight or obesity was associated with lower healthcare costs versus untreated patients. While the company did not provide exact dollar savings or magnitude in the excerpt, the data supports cost-effectiveness and could bolster broader adoption.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
LLY0.40
More News
- Jim Cramer says this healthcare stock is still a buy. Plus, what to do with BNY
- Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15%
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- AI infrastructure stocks tumble. Here's a few reasons for the sell-off
- Ambani’s Jio seeks to raise $3.2B in what could be India’s biggest IPO
- Travis Kelce joined an activist group pushing Six Flags to consider a sale. The ‘Final Destination’-style death of a patron poured gas on the fire